PET Imaging of MMP Activation in AAA: First in-Human Evaluation

AAA 中 MMP 激活的 PET 成像:首次人体评估

基本信息

  • 批准号:
    10371169
  • 负责人:
  • 金额:
    $ 64.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-08-01 至 2025-03-31
  • 项目状态:
    未结题

项目摘要

Abstract Abdominal aortic aneurysms (AAA) are responsible for 10,000 documented deaths every year in the US. While most aneurysms are asymptomatic, highly lethal complications, rupture and dissection do occur in a subset of patients. Aneurysm diameter is the best-known predictor of its propensity to rupture, and accordingly, aneurysm repair is recommended for large, or symptomatic AAA. However, many ruptures occur in smaller aneurysms that do not meet the criteria for repair; and conversely, some larger aneurysms do not rupture. AAA treatment remains limited to surgical or endovascular repair, as several promising medical therapies have failed in clinical studies. As such, novel tools (e.g., molecular imaging) are needed to better risk stratify patients, develop effective medical therapies, and monitor therapeutic effectiveness. Matrix metalloproteinases (MMP) activation promotes vascular remodeling in AAA, in part through degradation of elastin and other matrix proteins. Our previous studies have established the feasibility of MMP-targeted imaging to detect vascular remodeling by micro single photon emission computed tomography (SPECT)/CT in murine models of aneurysm. However, a number of limitations of the SPECT tracer and technology precluded clinical translation for vascular imaging. To address these limitations, we developed a novel family of MMP- targeted tracers (RYM) with improved pharmacokinetics, including a first in the class positron emission tomography (PET) tracer, 64Cu-RYM2. Here, we seek to further develop, evaluate, and clinically translate 64Cu-RYM2 for first in human imaging studies in AAA, hypothesizing that MMP PET/CT imaging with 64Cu- RYM2 can detect AAA MMP activity. Our specific aims are to evaluate 64Cu-RYM2 binding to human AAA tissue; address 64Cu-RYM2 pharmacokinetics and imaging performance in murine AAA in relation to tissue MMP activity; and translate 64Cu-RYM2 for human AAA imaging. Leveraging the resources and complementary expertise of the PIs and co-investigators at Yale School of Medicine and Washington University, including an NIBIB-funded P41- center at Washington University, these studies will establish the potential of 64Cu-RYM2 to quantify MMP activation in human AAA, and set the stage for a multi-center trial of MMP PET/CT imaging for AAA risk stratification.
摘要 腹主动脉瘤(AAA)每年造成10,000例有记录的死亡, 我们虽然大多数动脉瘤是无症状的,但高致命性并发症、破裂和夹层确实发生在动脉瘤患者中。 患者的子集。动脉瘤直径是其破裂倾向的最佳预测因子, 因此,建议对较大或有症状的AAA进行动脉瘤修复。然而,许多断裂 发生在不符合修复标准的较小动脉瘤中;相反,一些较大的动脉瘤 不要破裂。AAA治疗仍然局限于外科手术或腔内修复术,因为一些有前途的医疗 治疗在临床研究中失败了。因此,新颖的工具(例如,分子成像),以更好地风险 对患者进行分层,开发有效的医学疗法,并监测治疗效果。矩阵 基质金属蛋白酶(MMP)激活促进AAA血管重塑,部分是通过降解 弹性蛋白和其他基质蛋白。我们以前的研究已经建立了MMP靶向治疗的可行性, 通过微型单光子发射计算机断层扫描(SPECT)/CT成像检测血管重塑, 动脉瘤的小鼠模型。然而,SPECT示踪剂和技术的许多限制排除了 血管成像的临床翻译。为了解决这些局限性,我们开发了一个新的MMP家族, 靶向示踪剂(RYM)具有改善的药代动力学,包括一流的正电子发射 断层扫描(PET)示踪剂64 Cu-RYM 2。在这里,我们寻求进一步发展,评估和临床翻译 64 Cu-RYM 2首次用于AAA的人体成像研究,假设使用64 Cu-RYM 2的MMP PET/CT成像 RYM 2可检测AAA MMP活性。我们的具体目标是评估64 Cu-RYM 2与人AAA的结合 组织;说明64 Cu-RYM 2在小鼠AAA中的药代动力学和成像性能与组织的关系 MMP活性;并翻译64 Cu-RYM 2用于人AAA成像。利用资源和 耶鲁医学院和华盛顿的PI和合作研究者的互补专业知识 包括华盛顿大学NIBIB资助的P41中心,这些研究将建立 64 Cu-RYM 2定量人AAA中MMP活化的潜力,并为多中心试验奠定基础。 MMP PET/CT成像用于AAA风险分层。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Robert J. Gropler其他文献

Vulnerable or High-Risk Plaque: A emJACC: Cardiovascular Imaging/em Position Statement
易损或高危斑块:JACC:心血管影像学立场声明
  • DOI:
    10.1016/j.jcmg.2024.12.004
  • 发表时间:
    2025-06-01
  • 期刊:
  • 影响因子:
    15.200
  • 作者:
    Rocco Vergallo;Seung-Jung Park;Gregg W. Stone;David Erlinge;Italo Porto;Ron Waksman;Gary S. Mintz;Fabrizio D’Ascenzo;Sara Seitun;Luca Saba;Rozemarijn Vliegenthart;Fernando Alfonso;Armin Arbab-Zadeh;Peter Libby;Marcelo F. Di Carli;James E. Muller;Gerald Maurer;Robert J. Gropler;Y.S. Chandrashekhar;Eugene Braunwald;Ik-Kyung Jang
  • 通讯作者:
    Ik-Kyung Jang
Recovery of contractile function in viable but dysfunctional myocardium is dependent upon maintenance of oxidative metabolism
  • DOI:
    10.1016/0735-1097(90)92527-9
  • 发表时间:
    1990-02-01
  • 期刊:
  • 影响因子:
  • 作者:
    Robert J. Gropler;Barry A. Siegel;Julio E. Perez;Steven R. Bergmann;Robert G. Kopitsky;Burton E. Sobel;Edward M. Geltman
  • 通讯作者:
    Edward M. Geltman
Myocardial Perfusion PET for the Detection and Reporting of Coronary Microvascular Dysfunction: A emJACC: Cardiovascular Imaging/em Expert Panel Statement
心肌灌注正电子发射断层扫描在冠状动脉微血管功能障碍检测和报告中的应用:JACC:心血管影像学专家小组声明
  • DOI:
    10.1016/j.jcmg.2022.12.015
  • 发表时间:
    2023-04-01
  • 期刊:
  • 影响因子:
    15.200
  • 作者:
    Thomas H. Schindler;William F. Fearon;Matthieu Pelletier-Galarneau;Giuseppe Ambrosio;Udo Sechtem;Terrence D. Ruddy;Krishna K. Patel;Deepak L. Bhatt;Timothy M. Bateman;Henry Gewirtz;Jamshid Shirani;Juhani Knuuti;Robert J. Gropler;Panithaya Chareonthaitawee;Riemer H.J.A. Slart;Stephan Windecker;Philipp A. Kaufmann;Maria R. Abraham;Viviany R. Taqueti;Thomas J. Ford;Vasken Dilsizian
  • 通讯作者:
    Vasken Dilsizian
Journey to find the ideal PET flow tracer for clinical use: Are we there yet?
  • DOI:
    10.1016/j.nuclcard.2007.09.019
  • 发表时间:
    2007-11-01
  • 期刊:
  • 影响因子:
    2.700
  • 作者:
    David K. Glover;Robert J. Gropler
  • 通讯作者:
    Robert J. Gropler
Ninth nuclear cardiology invitational conference, Annapolis, Maryland, 2008
  • DOI:
    10.1007/bf03007373
  • 发表时间:
    2008-11-01
  • 期刊:
  • 影响因子:
    2.700
  • 作者:
    Ernest V. Garcia;Robert J. Gropler
  • 通讯作者:
    Robert J. Gropler

Robert J. Gropler的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Robert J. Gropler', 18)}}的其他基金

PET Imaging of MMP Activation in AAA: First in-Human Evaluation
AAA 中 MMP 激活的 PET 成像:首次人体评估
  • 批准号:
    10226098
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms
CCR2 靶向分子成像和腹主动脉瘤治疗
  • 批准号:
    10487405
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
  • 批准号:
    9905207
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
  • 批准号:
    10565938
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms
CCR2 靶向分子成像和腹主动脉瘤治疗
  • 批准号:
    10219893
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
  • 批准号:
    10361392
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
PET Imaging of MMP Activation in AAA: First in-Human Evaluation
AAA 中 MMP 激活的 PET 成像:首次人体评估
  • 批准号:
    10617801
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
PET Detection of CCR2 in Human Atherosclerosis
PET 检测人动脉粥样硬化中的 CCR2
  • 批准号:
    10091521
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
CCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic Aneurysms
CCR2 靶向分子成像和腹主动脉瘤治疗
  • 批准号:
    10673716
  • 财政年份:
    2020
  • 资助金额:
    $ 64.94万
  • 项目类别:
THE PET RADIOTRACER TRANSLATION AND RESOURCE CENTER (PET-RTRC)
PET 放射示踪剂翻译和资源中心 (PET-RTRC)
  • 批准号:
    10480874
  • 财政年份:
    2018
  • 资助金额:
    $ 64.94万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 64.94万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了